For Investors
Investors
Mentara Bio has completed a Series A funding round to support the development of MN-301, a glutamate modulator for epilepsy, up to the IND filing stage. We are currently in the midst of a Series B round to fund the development of MN-301 through Phase 2 clinical trials. For more details, please contact Sahil Velivelli (CEO) at: info@mentarabio.com
Our cutting-edge synthetic approach is being applied to MN-301 for epilepsy, highlighting its potential across various therapeutic areas. We are dedicated to leveraging our team’s expertise to acquire promising new therapies or collaborate with companies and inventors who share our commitment to innovation.
Mentara Bio Inc. Initiates Phase 2 Study of MN-301, an Innovative Antiepileptic Compound
May 13, 2024
Mentara Bio, a clinical-stage biopharmaceutical company focused on developing neurocircuit-selective medicines for neurological disorders, announced today its plans to commence a Phase 2 clinical trial of MN-301 for the treatment of epilepsy. MN-301 is a novel, highly selective compound targeting specific receptors involved in epilepsy pathways, developed in collaboration with leading academic institutions.
Mentara Bio Inc. Announces Closing of Series A Financing
March 06, 2023
Mentara Bio Inc. (“Mentara Bio” or the “Company”), a biopharmaceutical company committed to developing innovative treatments for neurological conditions, today announced the successful closing of its $4.1 million Series A financing round. This funding will enable the Company to complete the necessary IND-enabling studies for its lead product candidate, MN-045, in preparation for Phase 1 clinical trials planned for the latter half of 2023.
Mentara Bio Inc. Launches to Develop Advanced Treatments for Epilepsy and Dravet Syndrome
February 15, 2022
Mentara Bio Inc. (“Mentara Bio” or “the Company”), a pioneering biopharmaceutical firm, is proud to announce its official launch with a dedicated mission to develop innovative treatments for epilepsy and related neurological disorders, including Dravet syndrome. The Company’s leading candidate, MN-045, has demonstrated exceptional promise in preclinical studies and is on the path to an Investigational New Drug (IND) application, supported by $2M in Small Business Innovation Research (SBIR) awards.